MBHB Partner Kevin Noonan on the FTC’s efforts to delist drug device patents from the Orange Book

In Competition Policy International’s Antitrust Chronicle, MBHB Partner Kevin Noonan discusses the Federal Trade Commission’s push against drug device patents listed in the Food and Drug Administration’s “Orange Book,” highlighting the potential impact on innovation and patients. Read more here.